GlassScriptPhysician profile
Katherine B Windham
NPI 1942296512
$2,628.06
in general payments reported to CMS, 2019-2025
25 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $445 · 2021: $554 · 2022: $301 · 2023: $401 · 2024: $315 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $414.17 | 2020-2025 | Trintellix |
| Pfizer INC. | $303.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $235.82 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $225.52 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $211.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $194.66 | 2020-2025 | Airsupra, Breztri |
| Amgen INC. | $181.19 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $167.62 | 2021-2023 | Ubrelvy |
| Esperion Therapeutics, INC. | $121.62 | 2021-2025 | Nexletol |
| Adlon Therapeutics L.P. | $97.48 | 2019-2021 | |
| Dexcom, INC. | $64.18 | 2021 | |
| Mylan Specialty L.P. | $60.05 | 2019-2024 | Yupelri |
| Abbott Laboratories | $40.95 | 2021-2025 | Freestyle Libre 3 |
| Biosense Webster, INC. | $40.01 | 2024 | Carto 3 |
| Exact Sciences Corporation | $31.79 | 2023-2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.05 | 2024-2025 | Jardiance |
| Radius Health, INC. | $30.63 | 2025 | Tymlos |
| Eisai INC. | $30.33 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $27.20 | 2022 | |
| Shire North American Group INC | $23.34 | 2019 | |
| Viatris Specialty LLC | $21.38 | 2025 | Yupelri |
| Assertio Therapeutics, INC. | $20.09 | 2019 | |
| Aytu Biopharma, INC. | $18.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.01 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $17.06 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Windham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.